{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T01:16:50Z","timestamp":1788225410050,"version":"build-2803163510"},"reference-count":176,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:00:00Z","timestamp":1781827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":74,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82403852"],"award-info":[{"award-number":["82403852"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004731","name":"Natural Science Foundation of Zhejiang Province","doi-asserted-by":"publisher","award":["LQN25H160036"],"award-info":[{"award-number":["LQN25H160036"]}],"id":[{"id":"10.13039\/501100004731","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2024YFA1306400"],"award-info":[{"award-number":["2024YFA1306400"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"name":"the Joint Fund for Regional Innovation and Development of National Natural Science Foundation of China","award":["U23A20462"],"award-info":[{"award-number":["U23A20462"]}]},{"name":"\u201cLing Yan\u201d Research and Development Program of Department of Zhejiang Province Science and Technology","award":["2024C03167"],"award-info":[{"award-number":["2024C03167"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Exp Hematol Oncol"],"DOI":"10.1186\/s40164-026-00793-1","type":"journal-article","created":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T06:28:59Z","timestamp":1781850539000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Breathing new life into T-cell receptor-engineered T-cell therapy in solid tumors: enhancing strategies to expand the universality of precision therapy"],"prefix":"10.1186","volume":"15","author":[{"given":"Yawen","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaozhen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jieru","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingbo","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueli","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,19]]},"reference":[{"issue":"1","key":"793_CR1","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s13045-024-01544-7","volume":"17","author":"H Lin","year":"2024","unstructured":"Lin H, Liu C, Hu A, Zhang D, Yang H, Mao Y. Understanding the immunosuppressive microenvironment of glioma: Mechanistic insights and clinical perspectives. J Hematol Oncol. 2024;17(1):31.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"793_CR2","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s40164-024-00539-x","volume":"13","author":"Y Yin","year":"2024","unstructured":"Yin Y, Feng W, Chen J, Chen X, Wang G, Wang S, et al. Immunosuppressive tumor microenvironment in the progression, metastasis, and therapy of hepatocellular carcinoma: From bench to bedside. Exp Hematol Oncol. 2024;13(1):72.","journal-title":"Exp Hematol Oncol"},{"issue":"1","key":"793_CR3","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s40164-024-00490-x","volume":"13","author":"Z Liu","year":"2024","unstructured":"Liu Z, Lei W, Wang H, Liu X, Fu R. Challenges and strategies associated with CAR-T cell therapy in blood malignancies. Exp Hematol Oncol. 2024;13(1):22.","journal-title":"Exp Hematol Oncol"},{"issue":"1","key":"793_CR4","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s13045-024-01625-7","volume":"17","author":"K Ai","year":"2024","unstructured":"Ai K, Liu B, Chen X, Huang C, Yang L, Zhang W, et al. Optimizing CAR-T cell therapy for solid tumors: Current challenges and potential strategies. J Hematol Oncol. 2024;17(1):105.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"793_CR5","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s40164-024-00504-8","volume":"13","author":"W Shao","year":"2024","unstructured":"Shao W, Yao Y, Yang L, Li X, Ge T, Zheng Y, et al. Novel insights into TCR-T cell therapy in solid neoplasms: Optimizing adoptive immunotherapy. Exp Hematol Oncol. 2024;13(1):37.","journal-title":"Exp Hematol Oncol"},{"issue":"3","key":"793_CR6","doi-asserted-by":"publisher","first-page":"e008640","DOI":"10.1136\/jitc-2023-008640","volume":"12","author":"V Albarr\u00e1n Fern\u00e1ndez","year":"2024","unstructured":"Albarr\u00e1n Fern\u00e1ndez V, Ballest\u00edn Mart\u00ednez P, Stoltenborg Granh\u00f8j J, Borch TH, Donia M, Marie Svane I. Biomarkers for response to TIL therapy: A comprehensive review. J Immunother Cancer. 2024;12(3):e008640.","journal-title":"J Immunother Cancer"},{"issue":"8","key":"793_CR7","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1016\/j.ccell.2024.06.015","volume":"42","author":"AA Sarnaik","year":"2024","unstructured":"Sarnaik AA, Hwu P, Mul\u00e9 JJ, Pilon-Thomas S. Tumor-infiltrating lymphocytes: a new hope. Cancer Cell. 2024;42(8):1315\u20138.","journal-title":"Cancer Cell"},{"issue":"46","key":"793_CR8","doi-asserted-by":"publisher","first-page":"e2409356","DOI":"10.1002\/advs.202409356","volume":"11","author":"W Hu","year":"2024","unstructured":"Hu W, Bian Y, Ji H. TIL therapy in lung cancer: current progress and perspectives. Adv Sci. 2024;11(46):e2409356.","journal-title":"Adv Sci"},{"issue":"23","key":"793_CR9","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1056\/NEJMoa1609279","volume":"375","author":"E Tran","year":"2016","unstructured":"Tran E, Robbins PF, Lu Y-C, Prickett TD, Gartner JJ, Jia L, et al. T-cell transfer therapy targeting mutant KRAS in cancer. N Engl J Med. 2016;375(23):2255\u201362.","journal-title":"N Engl J Med"},{"issue":"20","key":"793_CR10","doi-asserted-by":"publisher","first-page":"2389","DOI":"10.1200\/JCO.2016.66.7220","volume":"34","author":"SL Goff","year":"2016","unstructured":"Goff SL, Dudley ME, Citrin DE, Somerville RP, Wunderlich JR, Danforth DN, et al. Randomized, prospective evaluation comparing intensity of lymphodepletion before adoptive transfer of tumor-infiltrating lymphocytes for patients with metastatic melanoma. J Clin Oncol. 2016;34(20):2389\u201397.","journal-title":"J Clin Oncol"},{"key":"793_CR11","doi-asserted-by":"publisher","first-page":"117252","DOI":"10.1016\/j.biopha.2024.117252","volume":"178","author":"H Lin","year":"2024","unstructured":"Lin H, Yang X, Ye S, Huang L, Mu W. Antigen escape in CAR-T cell therapy: mechanisms and overcoming strategies. Biomed Pharmacother. 2024;178:117252.","journal-title":"Biomed Pharmacother"},{"issue":"6","key":"793_CR12","first-page":"530","volume":"5","author":"J Liu","year":"2024","unstructured":"Liu J, Jiao X, Ma D, Fang Y, Gao Q. CAR-T therapy and targeted treatments: emerging combination strategies in solid tumors. Medicine (Baltimore). 2024;5(6):530\u201349.","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"793_CR13","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s40164-024-00576-6","volume":"13","author":"J Pu","year":"2024","unstructured":"Pu J, Liu T, Sharma A, Jiang L, Wei F, Ren X, et al. Advances in adoptive cellular immunotherapy and therapeutic breakthroughs in multiple myeloma. Exp Hematol Oncol. 2024;13(1):105.","journal-title":"Exp Hematol Oncol"},{"issue":"1","key":"793_CR14","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s40164-025-00662-3","volume":"14","author":"K Hushmandi","year":"2025","unstructured":"Hushmandi K, Imani Fooladi AA, Reiter RJ, Farahani N, Liang L, Aref AR, et al. Next-generation immunotherapeutic approaches for blood cancers: exploring the efficacy of CAR-T and cancer vaccines. Exp Hematol Oncol. 2025;14(1):75.","journal-title":"Exp Hematol Oncol"},{"issue":"4","key":"793_CR15","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.apsb.2018.03.001","volume":"8","author":"Z Zhao","year":"2018","unstructured":"Zhao Z, Chen Y, Francisco NM, Zhang Y, Wu M. The application of CAR-T cell therapy in hematological malignancies: advantages and challenges. Acta Pharm Sin B. 2018;8(4):539\u201351.","journal-title":"Acta Pharm Sin B"},{"issue":"1","key":"793_CR16","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1056\/NEJMra1706169","volume":"379","author":"CH June","year":"2018","unstructured":"June CH, Sadelain M. Chimeric antigen receptor therapy. N Engl J Med. 2018;379(1):64\u201373.","journal-title":"N Engl J Med"},{"issue":"1","key":"793_CR17","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s40164-025-00679-8","volume":"14","author":"C Yang","year":"2025","unstructured":"Yang C, Liu Y, Huang Z, Liu S, Zhang X, Liu Q, et al. Recent advances and challenges of cellular immunotherapies in lung cancer treatment. Exp Hematol Oncol. 2025;14(1):94.","journal-title":"Exp Hematol Oncol"},{"issue":"1","key":"793_CR18","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s40164-025-00683-y","volume":"14","author":"Y Liu","year":"2025","unstructured":"Liu Y, Duan Y, Du Z, Lu B, Liu S, Li L, et al. Current challenges and emerging opportunities of chimeric antigen receptor-engineered cell immunotherapy. Exp Hematol Oncol. 2025;14(1):92.","journal-title":"Exp Hematol Oncol"},{"issue":"1","key":"793_CR19","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s40164-024-00564-w","volume":"13","author":"X Li","year":"2024","unstructured":"Li X, Chen T, Li X, Zhang H, Li Y, Zhang S, et al. Therapeutic targets of armored chimeric antigen receptor T cells navigating the tumor microenvironment. Exp Hematol Oncol. 2024;13(1):96.","journal-title":"Exp Hematol Oncol"},{"issue":"8","key":"793_CR20","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1016\/j.jcyt.2024.03.484","volume":"26","author":"GC Russell","year":"2024","unstructured":"Russell GC, Hamzaoui Y, Rho D, Sutrave G, Choi JS, Missan DS, et al. Synthetic biology approaches for enhancing safety and specificity of CAR-T cell therapies for solid cancers. Cytotherapy. 2024;26(8):842\u201357.","journal-title":"Cytotherapy"},{"key":"793_CR21","doi-asserted-by":"publisher","first-page":"103020","DOI":"10.1016\/j.copbio.2023.103020","volume":"84","author":"M Hong","year":"2023","unstructured":"Hong M, Talluri S, Chen YY. Advances in promoting chimeric antigen receptor T cell trafficking and infiltration of solid tumors. Curr Opin Biotechnol. 2023;84:103020.","journal-title":"Curr Opin Biotechnol"},{"issue":"7","key":"793_CR22","doi-asserted-by":"publisher","first-page":"eadf3700","DOI":"10.1126\/sciadv.adf3700","volume":"9","author":"E Baulu","year":"2023","unstructured":"Baulu E, Gardet C, Chuvin N, Depil S. TCR-engineered T cell therapy in solid tumors: state of the art and perspectives. Sci Adv. 2023;9(7):eadf3700.","journal-title":"Sci Adv"},{"key":"793_CR23","doi-asserted-by":"publisher","first-page":"215840","DOI":"10.1016\/j.canlet.2022.215840","volume":"546","author":"R Xu","year":"2022","unstructured":"Xu R, Du S, Zhu J, Meng F, Liu B. Neoantigen-targeted TCR-T cell therapy for solid tumors: how far from clinical application. Cancer Lett. 2022;546:215840.","journal-title":"Cancer Lett"},{"key":"793_CR24","doi-asserted-by":"publisher","first-page":"114224","DOI":"10.1016\/j.ejca.2024.114224","volume":"209","author":"P Ma","year":"2024","unstructured":"Ma P, Jiang Y, Zhao G, Wang W, Xing S, Tang Q, et al. Toward a comprehensive solution for treating solid tumors using T-cell receptor therapy: a review. Eur J Cancer. 2024;209:114224.","journal-title":"Eur J Cancer"},{"issue":"9","key":"793_CR25","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.it.2023.07.005","volume":"44","author":"Y Sykulev","year":"2023","unstructured":"Sykulev Y. Factors contributing to the potency of CD8+ T cells. Trends Immunol. 2023;44(9):693\u2013700.","journal-title":"Trends Immunol"},{"issue":"1","key":"793_CR26","doi-asserted-by":"publisher","first-page":"1929726","DOI":"10.1080\/2162402X.2021.1929726","volume":"10","author":"T Wei","year":"2021","unstructured":"Wei T, Leisegang M, Xia M, Kiyotani K, Li N, Zeng C, et al. Generation of neoantigen-specific T cells for adoptive cell transfer for treating head and neck squamous cell carcinoma. OncoImmunology. 2021;10(1):1929726.","journal-title":"OncoImmunology"},{"issue":"9","key":"793_CR27","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1007\/s00262-024-03749-8","volume":"73","author":"Z Li","year":"2024","unstructured":"Li Z, Ma L, Gao Z, Wang X, Che X, Zhang P, et al. Identification and validation of tumor-specific T cell receptors from tumor infiltrating lymphocytes using tumor organoid co-cultures. Cancer Immunol Immunother. 2024;73(9):164\u201376.","journal-title":"Cancer Immunol Immunother"},{"issue":"6","key":"793_CR28","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1038\/s41422-022-00627-9","volume":"32","author":"J He","year":"2022","unstructured":"He J, Xiong X, Yang H, Li D, Liu X, Li S, et al. Defined tumor antigen-specific T cells potentiate personalized TCR-T cell therapy and prediction of immunotherapy response. Cell Res. 2022;32(6):530\u201342.","journal-title":"Cell Res"},{"issue":"16","key":"793_CR29","doi-asserted-by":"publisher","first-page":"3333","DOI":"10.1016\/j.cell.2023.06.020","volume":"186","author":"G Dolton","year":"2023","unstructured":"Dolton G, Rius C, Wall A, Szomolay B, Bianchi V, Galloway SAE, et al. Targeting of multiple tumor-associated antigens by individual T cell receptors during successful cancer immunotherapy. Cell. 2023;186(16):3333-49.e27.","journal-title":"Cell"},{"issue":"7","key":"793_CR30","doi-asserted-by":"publisher","first-page":"e008668","DOI":"10.1136\/jitc-2023-008668","volume":"12","author":"M Wermke","year":"2024","unstructured":"Wermke M, Holderried TAW, Luke JJ, Morris VK, Alsdorf WH, Wetzko K, et al. First-in-human dose escalation trial to evaluate the clinical safety and efficacy of an anti-MAGEA1 autologous TCR-transgenic T cell therapy in relapsed and refractory solid tumors. J Immunother Cancer. 2024;12(7):e008668.","journal-title":"J Immunother Cancer"},{"issue":"6","key":"793_CR31","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.1053\/j.gastro.2019.01.251","volume":"156","author":"AT Tan","year":"2019","unstructured":"Tan AT, Yang N, Lee Krishnamoorthy T, Oei V, Chua A, Zhao X, et al. Use of expression profiles of HBV-DNA integrated into genomes of hepatocellular carcinoma cells to select T cells for immunotherapy. Gastroenterology. 2019;156(6):1862-76.e9.","journal-title":"Gastroenterology"},{"issue":"11","key":"793_CR32","doi-asserted-by":"publisher","first-page":"e010248","DOI":"10.1136\/jitc-2024-010248","volume":"12","author":"M Liu","year":"2024","unstructured":"Liu M, Akahori Y, Imai N, Wang L, Negishi K, Kato T, et al. MAGE-A4 pMHC-targeted CAR-T cells exploiting TCR machinery exhibit significantly improved in vivo function while retaining antigen specificity. J Immunother Cancer. 2024;12(11):e010248.","journal-title":"J Immunother Cancer"},{"issue":"1","key":"793_CR33","doi-asserted-by":"publisher","first-page":"507","DOI":"10.4049\/jimmunol.163.1.507","volume":"163","author":"TM Clay","year":"1999","unstructured":"Clay TM, Custer MC, Sachs J, Hwu P, Rosenberg SA, Nishimura MI. Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers anti-tumor reactivity. J Immunol. 1999;163(1):507\u201313.","journal-title":"J Immunol"},{"issue":"1","key":"793_CR34","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1002\/(SICI)1097-0142(19990225)87:1<37::AID-CNCR7>3.0.CO;2-7","volume":"87","author":"PA Fetsch","year":"1999","unstructured":"Fetsch PA, Marincola FM, Filie A, Hijazi YM, Kleiner DE, Abati A. Melanoma-associated antigen recognized by T cells (MART-1): the advent of a preferred immunocytochemical antibody for the diagnosis of metastatic malignant melanoma with fine-needle aspiration. Cancer. 1999;87(1):37\u201342.","journal-title":"Cancer"},{"issue":"3","key":"793_CR35","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1038\/s41591-020-01225-1","volume":"27","author":"NB Nagarsheth","year":"2021","unstructured":"Nagarsheth NB, Norberg SM, Sinkoe AL, Adhikary S, Meyer TJ, Lack JB, et al. TCR-engineered T cells targeting E7 for patients with metastatic HPV-associated epithelial cancers. Nat Med. 2021;27(3):419\u201325.","journal-title":"Nat Med"},{"issue":"10435","key":"793_CR36","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1016\/S0140-6736(24)00319-2","volume":"403","author":"SP D'Angelo","year":"2024","unstructured":"D\u2019Angelo SP, Araujo DM, Abdul Razak AR, Agulnik M, Attia S, Blay J-Y, et al. Afamitresgene autoleucel for advanced synovial sarcoma and myxoid round cell liposarcoma (SPEARHEAD-1): an international, open-label, phase 2 trial. Lancet. 2024;403(10435):1460\u201371.","journal-title":"Lancet"},{"issue":"5","key":"793_CR37","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1158\/1078-0432.CCR-14-2708","volume":"21","author":"PF Robbins","year":"2015","unstructured":"Robbins PF, Kassim SH, Tran TLN, Crystal JS, Morgan RA, Feldman SA, et al. A pilot trial using lymphocytes genetically engineered with an NY-ESO-1\u2013reactive T-cell receptor: long-term follow-up and correlates with response. Clin Cancer Res. 2015;21(5):1019\u201327.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"793_CR38","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.ccell.2023.12.011","volume":"42","author":"ET Goddard","year":"2024","unstructured":"Goddard ET, Linde MH, Srivastava S, Klug G, Shabaneh TB, Iannone S, et al. Immune evasion of dormant disseminated tumor cells is due to their scarcity and can be overcome by T cell immunotherapies. Cancer Cell. 2024;42(1):119-34.e12.","journal-title":"Cancer Cell"},{"issue":"3","key":"793_CR39","doi-asserted-by":"publisher","first-page":"e002035","DOI":"10.1136\/jitc-2020-002035","volume":"9","author":"K Davari","year":"2021","unstructured":"Davari K, Holland T, Prassmayer L, Longinotti G, Ganley KP, Pechilis LJ, et al. Development of a CD8 co-receptor independent T-cell receptor specific for tumor-associated antigen MAGE-A4 for next generation T-cell-based immunotherapy. J Immunother Cancer. 2021;9(3):e002035.","journal-title":"J Immunother Cancer"},{"issue":"3","key":"793_CR40","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1158\/1078-0432.CCR-24-1591","volume":"31","author":"M Altan","year":"2025","unstructured":"Altan M, Lopes G, Hiltermann TJN, Govindan R, Villaruz LC, Calvo E, et al. Safety and tolerability of letetresgene autoleucel (GSK3377794): pilot studies in patients with advanced non-small cell lung cancer. Clin Cancer Res. 2025;31(3):529\u201342.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"793_CR41","doi-asserted-by":"publisher","first-page":"e003581","DOI":"10.1136\/jitc-2021-003581","volume":"10","author":"GR Blumenschein","year":"2022","unstructured":"Blumenschein GR, Devarakonda S, Johnson M, Moreno V, Gainor J, Edelman MJ, et al. Phase I clinical trial evaluating the safety and efficacy of ADP-A2M10 SPEAR T cells in patients with MAGE-A10+ advanced non-small cell lung cancer. J Immunother Cancer. 2022;10(1):e003581.","journal-title":"J Immunother Cancer"},{"issue":"12","key":"793_CR42","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1158\/2326-6066.CIR-14-0108","volume":"2","author":"P Simon","year":"2014","unstructured":"Simon P, Omokoko TA, Breitkreuz A, Hebich L, Kreiter S, Attig S, et al. Functional TCR retrieval from single antigen-specific human T cells reveals multiple novel epitopes. Cancer Immunol Res. 2014;2(12):1230\u201344.","journal-title":"Cancer Immunol Res"},{"issue":"3","key":"793_CR43","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.jcyt.2023.12.002","volume":"26","author":"P Shafer","year":"2024","unstructured":"Shafer P, Leung WK, Woods M, Choi JM, Rodriguez-Plata CM, Maknojia A, et al. Incongruity between T cell receptor recognition of breast cancer hotspot mutations ESR1 Y537S and D538G following exogenous peptide loading versus endogenous antigen processing. Cytotherapy. 2024;26(3):266\u201375.","journal-title":"Cytotherapy"},{"issue":"23\u201324","key":"793_CR44","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1089\/hum.2023.035","volume":"34","author":"J Festag","year":"2023","unstructured":"Festag J, Festag MM, Asen T, Wettengel JM, M\u00fcck-H\u00e4usl MA, Abdulhaqq S, et al. Vector-mediated delivery of human major histocompatibility complex-I into hepatocytes enables investigation of T cell receptor-redirected hepatitis B virus-specific T cells in mice, and in macaque cell cultures. Hum Gene Ther. 2023;34(23\u201324):1204\u201318.","journal-title":"Hum Gene Ther"},{"issue":"11","key":"793_CR45","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1016\/j.humimm.2022.08.006","volume":"83","author":"S Xia","year":"2022","unstructured":"Xia S, Huang J, Yan L, Han J, Zhang W, Shao H, et al. miR-150 promotes progressive T cell differentiation via inhibiting FOXP1 and RC3H1. Hum Immunol. 2022;83(11):778\u201388.","journal-title":"Hum Immunol"},{"issue":"9","key":"793_CR46","doi-asserted-by":"publisher","first-page":"e1419","DOI":"10.1002\/cti2.1419","volume":"11","author":"C Zhang","year":"2022","unstructured":"Zhang C, Sun Y, Li S, Shen L, Teng X, Xiao Y, et al. Autophagic flux restoration of senescent T cells improves antitumor activity of TCR\u2010engineered T cells. Clin Transl Immunol. 2022;11(9):e1419.","journal-title":"Clin Transl Immunol"},{"issue":"4","key":"793_CR47","doi-asserted-by":"publisher","first-page":"e13389","DOI":"10.1111\/cpr.13389","volume":"56","author":"B Wu","year":"2023","unstructured":"Wu B, Zhang Q, Hong P, Liu L, Peng H, Xia C, et al. Antigen\u2010specific TCR\u2010T cells from Rag2 gene\u2010deleted pluripotent stem cells impede solid tumour growth in a mouse model. Cell Prolif. 2023;56(4):e13389.","journal-title":"Cell Prolif"},{"issue":"6","key":"793_CR48","doi-asserted-by":"publisher","first-page":"e003811","DOI":"10.1136\/jitc-2021-003811","volume":"10","author":"M Ishihara","year":"2022","unstructured":"Ishihara M, Kitano S, Kageyama S, Miyahara Y, Yamamoto N, Kato H, et al. NY-ESO-1-specific redirected T cells with endogenous TCR knockdown mediate tumor response and cytokine release syndrome. J Immunother Cancer. 2022;10(6):e003811.","journal-title":"J Immunother Cancer"},{"issue":"1","key":"793_CR49","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s40164-024-00543-1","volume":"13","author":"S Zheng","year":"2024","unstructured":"Zheng S, Wang W, Shen L, Yao Y, Xia W, Ni C. Tumor battlefield within inflamed, excluded or desert immune phenotypes: the mechanisms and strategies. Exp Hematol Oncol. 2024;13(1):80.","journal-title":"Exp Hematol Oncol"},{"issue":"12","key":"793_CR50","doi-asserted-by":"publisher","first-page":"5737","DOI":"10.21873\/anticanres.16780","volume":"43","author":"K Asanuma","year":"2023","unstructured":"Asanuma K, Ishihara M, Nakamura T, Uchida K, Hagi T, Kageyama S, et al. Histological assessment of synovial sarcoma before and after TCR-T Cell therapy and cryoablation: a case report. Anticancer Res. 2023;43(12):5737\u201348.","journal-title":"Anticancer Res"},{"issue":"3","key":"793_CR51","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1002\/path.6083","volume":"260","author":"T Minowa","year":"2023","unstructured":"Minowa T, Hirohashi Y, Murata K, Sasaki K, Handa T, Nakatsugawa M, et al. Fusion with type 2 macrophages induces melanoma cell heterogeneity that potentiates immunological escape from cytotoxic T lymphocytes. J Pathol. 2023;260(3):304\u201316.","journal-title":"J Pathol"},{"issue":"6","key":"793_CR52","doi-asserted-by":"publisher","first-page":"e008375","DOI":"10.1136\/jitc-2023-008375","volume":"12","author":"Y Chen","year":"2024","unstructured":"Chen Y, Ouyang D, Wang Y, Pan Q, Zhao J, Chen H, et al. EBV promotes TCR-T-cell therapy resistance by inducing CD163+M2 macrophage polarization and MMP9 secretion. J Immunother Cancer. 2024;12(6):e008375.","journal-title":"J Immunother Cancer"},{"issue":"631","key":"793_CR53","doi-asserted-by":"publisher","first-page":"eabg8070","DOI":"10.1126\/scitranslmed.abg8070","volume":"14","author":"MC Lahman","year":"2022","unstructured":"Lahman MC, Schmitt TM, Paulson KG, Vigneron N, Buenrostro D, Wagener FD, et al. Targeting an alternate Wilms\u2019 tumor antigen 1 peptide bypasses immunoproteasome dependency. Sci Transl Med. 2022;14(631):eabg8070.","journal-title":"Sci Transl Med"},{"issue":"12","key":"793_CR54","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1016\/j.trecan.2021.07.006","volume":"7","author":"L Maggs","year":"2021","unstructured":"Maggs L, Sadagopan A, Moghaddam AS, Ferrone S. HLA class I antigen processing machinery defects in antitumor immunity and immunotherapy. Trends Cancer. 2021;7(12):1089\u2013101.","journal-title":"Trends Cancer"},{"issue":"5796","key":"793_CR55","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1126\/science.1129003","volume":"314","author":"RA Morgan","year":"2006","unstructured":"Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, Sherry RM, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science. 2006;314(5796):126\u20139.","journal-title":"Science"},{"issue":"197","key":"793_CR56","doi-asserted-by":"publisher","first-page":"197ra03","DOI":"10.1126\/scitranslmed.3006034","volume":"5","author":"BJ Cameron","year":"2013","unstructured":"Cameron BJ, Gerry AB, Dukes J, Harper JV, Kannan V, Bianchi FC, et al. Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells. Sci Transl Med. 2013;5(197):197ra03.","journal-title":"Sci Transl Med"},{"issue":"6","key":"793_CR57","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1182\/blood-2013-03-490565","volume":"122","author":"GP Linette","year":"2013","unstructured":"Linette GP, Stadtmauer EA, Maus MV, Rapoport AP, Levine BL, Emery L, et al. Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. Blood. 2013;122(6):863\u201371.","journal-title":"Blood"},{"key":"793_CR58","doi-asserted-by":"publisher","DOI":"10.1126\/science.abl5282","author":"X Zhao","year":"2022","unstructured":"Zhao X, Kolawole EM, Chan W, Feng Y, Yang X, Gee MH, et al. Tuning T cell receptor sensitivity through catch bond engineering. Science. 2022. https:\/\/doi.org\/10.1126\/science.abl5282.","journal-title":"Science"},{"key":"793_CR59","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002716","author":"ST Kim","year":"2021","unstructured":"Kim ST, Tayar J, Fu S, Ke D, Norry E, Sun A, et al. Newly developed pseudogout arthritis after therapy with MAGE-A4 directed TCR T cells responded to treatment with tocilizumab. J Immunother Cancer. 2021. https:\/\/doi.org\/10.1136\/jitc-2021-002716.","journal-title":"J Immunother Cancer"},{"issue":"5","key":"793_CR60","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1038\/nm.2128","volume":"16","author":"GM Bendle","year":"2010","unstructured":"Bendle GM, Linnemann C, Hooijkaas AI, Bies L, de Witte MA, Jorritsma A, et al. Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy. Nat Med. 2010;16(5):565\u201370.","journal-title":"Nat Med"},{"issue":"1","key":"793_CR61","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1182\/blood-2006-03-013318","volume":"109","author":"MH Heemskerk","year":"2007","unstructured":"Heemskerk MH, Hagedoorn RS, van der Hoorn MA, van der Veken LT, Hoogeboom M, Kester MG, et al. Efficiency of T-cell receptor expression in dual-specific T cells is controlled by the intrinsic qualities of the TCR chains within the TCR-CD3 complex. Blood. 2007;109(1):235\u201343.","journal-title":"Blood"},{"issue":"5","key":"793_CR62","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1038\/nm.2700","volume":"18","author":"E Provasi","year":"2012","unstructured":"Provasi E, Genovese P, Lombardo A, Magnani Z, Liu PQ, Reik A, et al. Editing T cell specificity towards leukemia by zinc finger nucleases and lentiviral gene transfer. Nat Med. 2012;18(5):807\u201315.","journal-title":"Nat Med"},{"issue":"1","key":"793_CR63","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s40164-022-00291-0","volume":"11","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, Liu Z, Wei W, Li Y. TCR engineered T cells for solid tumor immunotherapy. Exp Hematol Oncol. 2022;11(1):38.","journal-title":"Exp Hematol Oncol"},{"issue":"1","key":"793_CR64","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s40164-025-00689-6","volume":"14","author":"R Wang","year":"2025","unstructured":"Wang R, Zhuang J, Zhang Q, Wu W, Yu X, Zhang H, et al. Decoding the metabolic dialogue in the tumor microenvironment: from immune suppression to precision cancer therapies. Exp Hematol Oncol. 2025;14(1):99.","journal-title":"Exp Hematol Oncol"},{"issue":"12","key":"793_CR65","doi-asserted-by":"publisher","first-page":"e89762","DOI":"10.1172\/jci.insight.89762","volume":"2","author":"A Pavesi","year":"2017","unstructured":"Pavesi A, Tan AT, Koh S, Chia A, Colombo M, Antonecchia E, et al. A 3D microfluidic model for preclinical evaluation of TCR-engineered T cells against solid tumors. JCI Insight. 2017;2(12):e89762.","journal-title":"JCI Insight"},{"key":"793_CR66","doi-asserted-by":"publisher","first-page":"416","DOI":"10.3389\/fimmu.2018.00416","volume":"9","author":"SWL Lee","year":"2018","unstructured":"Lee SWL, Adriani G, Ceccarello E, Pavesi A, Tan AT, Bertoletti A, et al. Characterizing the role of monocytes in T cell cancer immunotherapy using a 3D microfluidic model. Front Immunol. 2018;9:416.","journal-title":"Front Immunol"},{"issue":"2","key":"793_CR67","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.ymthe.2019.12.009","volume":"28","author":"FD Bushman","year":"2020","unstructured":"Bushman FD. Retroviral insertional mutagenesis in humans: evidence for four genetic mechanisms promoting expansion of cell clones. Mol Ther. 2020;28(2):352\u20136.","journal-title":"Mol Ther"},{"key":"793_CR68","doi-asserted-by":"crossref","unstructured":"Hacein-Bey-Abina S, Von Kalle C, Schmidt M, McCormack MP, Wulffraat N, Leboulch P, et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science (New York, NY).302 (5644):415\u20139.","DOI":"10.1126\/science.1088547"},{"issue":"2","key":"793_CR69","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1172\/JCI130144","volume":"130","author":"CL Nobles","year":"2019","unstructured":"Nobles CL, Sherrill-Mix S, Everett JK, Reddy S, Fraietta JA, Porter DL, et al. CD19-targeting CAR T cell immunotherapy outcomes correlate with genomic modification by vector integration. J Clin Invest. 2019;130(2):673\u201385.","journal-title":"J Clin Invest"},{"issue":"15","key":"793_CR70","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1182\/bloodadvances.2019000219","volume":"3","author":"NN Shah","year":"2019","unstructured":"Shah NN, Qin H, Yates B, Su L, Shalabi H, Raffeld M, et al. Clonal expansion of CAR T cells harboring lentivector integration in the CBL gene following anti-CD22 CAR T-cell therapy. Blood Adv. 2019;3(15):2317\u201322.","journal-title":"Blood Adv"},{"issue":"7953","key":"793_CR71","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1038\/s41586-022-05531-1","volume":"615","author":"SP Foy","year":"2022","unstructured":"Foy SP, Jacoby K, Bota DA, Hunter T, Pan Z, Stawiski E, et al. Non-viral precision T cell receptor replacement for personalized cell therapy. Nature. 2022;615(7953):687\u201396.","journal-title":"Nature"},{"issue":"2","key":"793_CR72","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.cell.2022.12.022","volume":"186","author":"WA Nyberg","year":"2023","unstructured":"Nyberg WA, Ark J, To A, Clouden S, Reeder G, Muldoon JJ, et al. An evolved AAV variant enables efficient genetic engineering of murine T cells. Cell. 2023;186(2):446-60.e19.","journal-title":"Cell"},{"issue":"1","key":"793_CR73","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s11684-018-0677-1","volume":"13","author":"S Kang","year":"2019","unstructured":"Kang S, Li Y, Bao Y, Li Y. High-affinity T cell receptors redirect cytokine-activated T cells (CAT) to kill cancer cells. Front Med. 2019;13(1):69\u201382.","journal-title":"Front Med"},{"issue":"4","key":"793_CR74","doi-asserted-by":"publisher","first-page":"100318","DOI":"10.1016\/j.jhepr.2021.100318","volume":"3","author":"K Healy","year":"2021","unstructured":"Healy K, Pavesi A, Parrot T, Sobkowiak MJ, Reinsbach SE, Davanian H, et al. Human MAIT cells endowed with HBV specificity are cytotoxic and migrate towards HBV-HCC while retaining antimicrobial functions. JHEP Rep. 2021;3(4):100318.","journal-title":"JHEP Rep"},{"issue":"13","key":"793_CR75","doi-asserted-by":"publisher","first-page":"4449","DOI":"10.7150\/thno.84710","volume":"13","author":"B Zhang","year":"2023","unstructured":"Zhang B, Ren Z, Zhao J, Zhu Y, Huang B, Xiao C, et al. Global analysis of HLA-A2 restricted MAGE-A3 tumor antigen epitopes and corresponding TCRs in non-small cell lung cancer. Theranostics. 2023;13(13):4449\u201368.","journal-title":"Theranostics"},{"issue":"4","key":"793_CR76","doi-asserted-by":"publisher","first-page":"e006334","DOI":"10.1136\/jitc-2022-006334","volume":"11","author":"P Chen","year":"2023","unstructured":"Chen P, Chen D, Bu D, Gao J, Qin W, Deng K, et al. Dominant neoantigen verification in hepatocellular carcinoma by a single-plasmid system coexpressing patient HLA and antigen. J Immunother Cancer. 2023;11(4):e006334.","journal-title":"J Immunother Cancer"},{"issue":"11","key":"793_CR77","doi-asserted-by":"publisher","first-page":"3686","DOI":"10.1111\/cas.15528","volume":"113","author":"J Jiang","year":"2022","unstructured":"Jiang J, Xia M, Zhang L, Chen X, Zhao Y, Zeng C, et al. Rapid generation of genetically engineered T cells for the treatment of virus-related cancers. Cancer Sci. 2022;113(11):3686\u201397.","journal-title":"Cancer Sci"},{"issue":"5","key":"793_CR78","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.ccell.2022.03.012","volume":"40","author":"KI Hanada","year":"2022","unstructured":"Hanada KI, Zhao C, Gil-Hoyos R, Gartner JJ, Chow-Parmer C, Lowery FJ, et al. A phenotypic signature that identifies neoantigen-reactive T cells in fresh human lung cancers. Cancer Cell. 2022;40(5):479\u201393.","journal-title":"Cancer Cell"},{"issue":"25","key":"793_CR79","doi-asserted-by":"publisher","first-page":"9697","DOI":"10.1021\/acs.analchem.3c01754","volume":"95","author":"Y Li","year":"2023","unstructured":"Li Y, Qi J, Liu Y, Zheng Y, Zhu H, Zang Y, et al. High-throughput screening of functional neo-antigens and their specific T-cell receptors via the Jurkat reporter system combined with droplet microfluidics. Anal Chem. 2023;95(25):9697\u2013705.","journal-title":"Anal Chem"},{"issue":"11","key":"793_CR80","doi-asserted-by":"publisher","first-page":"e2300730","DOI":"10.1002\/smtd.202300730","volume":"7","author":"J Qi","year":"2023","unstructured":"Qi J, Zhu H, Li Y, Guan X, He Y, Ren G, et al. Creation of a high\u2010throughput microfluidic platform for single\u2010cell transcriptome sequencing of cell\u2010cell interactions. Small Methods. 2023;7(11):e2300730.","journal-title":"Small Methods"},{"key":"793_CR81","doi-asserted-by":"publisher","first-page":"216741","DOI":"10.1016\/j.canlet.2024.216741","volume":"588","author":"X Wang","year":"2024","unstructured":"Wang X, Dai Z, Lin X, Zou X, Wang R, Tasiheng Y, et al. Antigen\/HLA-agnostic strategies for Characterizing Tumor-responsive T cell receptors in PDAC patients via single-cell sequencing and autologous organoid application. Cancer Lett. 2024;588:216741.","journal-title":"Cancer Lett"},{"issue":"2","key":"793_CR82","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1002\/hep.29844","volume":"68","author":"W Zhu","year":"2018","unstructured":"Zhu W, Peng Y, Wang L, Hong Y, Jiang X, Li Q, et al. Identification of \u03b1-fetoprotein-specific T-cell receptors for hepatocellular carcinoma immunotherapy. Hepatology. 2018;68(2):574\u201389.","journal-title":"Hepatology"},{"issue":"3","key":"793_CR83","doi-asserted-by":"publisher","first-page":"e118","DOI":"10.1002\/cai2.118","volume":"3","author":"Y Xu","year":"2024","unstructured":"Xu Y, Shan W, Luo Q, Zhang M, Huo D, Chen Y, et al. Establishment of a humanized mouse model using steady-state peripheral blood-derived hematopoietic stem and progenitor cells facilitates screening of cancer-targeted T-cell repertoires. Cancer Innovation. 2024;3(3):e118.","journal-title":"Cancer Innovation"},{"issue":"2","key":"793_CR84","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1093\/neuonc\/noad172","volume":"26","author":"C Kr\u00e4mer","year":"2024","unstructured":"Kr\u00e4mer C, Kilian M, Chih Y-C, Kourtesakis A, Hoffmann DC, Boschert T, et al. NLGN4X TCR transgenic T cells to treat gliomas. Neuro Oncol. 2024;26(2):266\u201378.","journal-title":"Neuro Oncol"},{"issue":"21","key":"793_CR85","doi-asserted-by":"publisher","first-page":"e175790","DOI":"10.1172\/JCI175790","volume":"134","author":"AS Bear","year":"2024","unstructured":"Bear AS, Nadler RB, O\u2019Hara MH, Stanton KL, Xu C, Saporito RJ, et al. Natural TCRs targeting KRASG12V display fine specificity and sensitivity to human solid tumors. J Clin Invest. 2024;134(21):e175790.","journal-title":"J Clin Invest"},{"key":"793_CR86","doi-asserted-by":"publisher","first-page":"1470130","DOI":"10.3389\/fimmu.2024.1470130","volume":"15","author":"S Sennikov","year":"2024","unstructured":"Sennikov S, Volynets M, Alrhmoun S, Perik-Zavodskii R, Perik-Zavodskaia O, Fisher M, et al. Modified dendritic cell-based T-cell expansion protocol and single-cell multi-omics allow for the selection of the most expanded and in vitro-effective clonotype via profiling of thousands of MAGE-A3-specific T-cells. Front Immunol. 2024;15:1470130.","journal-title":"Front Immunol"},{"issue":"1","key":"793_CR87","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1038\/s41467-024-46558-4","volume":"15","author":"J Long","year":"2024","unstructured":"Long J, Chen X, He M, Ou S, Zhao Y, Yan Q, et al. HLA-class II restricted TCR targeting human papillomavirus type 18 E7 induces solid tumor remission in mice. Nat Commun. 2024;15(1):2271.","journal-title":"Nat Commun"},{"issue":"1","key":"793_CR88","doi-asserted-by":"publisher","first-page":"10520","DOI":"10.1038\/s41467-024-53911-0","volume":"15","author":"F F\u00fcchsl","year":"2024","unstructured":"F\u00fcchsl F, Untch J, Kavaka V, Zuleger G, Braun S, Schwanzer A, et al. High-resolution profile of neoantigen-specific TCR activation links moderate stimulation to increased resilience of engineered TCR-T cells. Nat Commun. 2024;15(1):10520.","journal-title":"Nat Commun"},{"issue":"1","key":"793_CR89","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41421-022-00386-2","volume":"8","author":"L Wang","year":"2022","unstructured":"Wang L, Lan X. Rapid screening of TCR-pMHC interactions by the YAMTAD system. Cell Discov. 2022;8(1):30.","journal-title":"Cell Discov"},{"issue":"16","key":"793_CR90","doi-asserted-by":"publisher","first-page":"e2200169","DOI":"10.1002\/adhm.202200169","volume":"11","author":"JF Ashby","year":"2022","unstructured":"Ashby JF, Schmidt J, Kc N, Kurum A, Koch C, Harari A, et al. Microfluidic T cell selection by cellular avidity. Adv Healthcare Mater. 2022;11(16):e2200169.","journal-title":"Adv Healthcare Mater"},{"issue":"75","key":"793_CR91","doi-asserted-by":"publisher","first-page":"34132","DOI":"10.18632\/oncotarget.26139","volume":"9","author":"S Morimoto","year":"2018","unstructured":"Morimoto S, Fujiki F, Kondo K, Nakajima H, Kobayashi Y, Inatome M, et al. Establishment of a novel platform cell line for efficient and precise evaluation of T cell receptor functional avidity. Oncotarget. 2018;9(75):34132.","journal-title":"Oncotarget"},{"issue":"7","key":"793_CR92","doi-asserted-by":"publisher","first-page":"2347","DOI":"10.1007\/s00262-023-03420-8","volume":"72","author":"F Fujiki","year":"2023","unstructured":"Fujiki F, Morimoto S, Nishida Y, Tanii S, Aoyama N, Inatome M, et al. Establishment of a novel NFAT-GFP reporter platform useful for the functional avidity maturation of HLA class II-restricted TCRs. Cancer Immunol Immunother. 2023;72(7):2347\u201356.","journal-title":"Cancer Immunol Immunother"},{"issue":"6","key":"793_CR93","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1158\/2326-6066.CIR-17-0538","volume":"6","author":"K Miyao","year":"2018","unstructured":"Miyao K, Terakura S, Okuno S, Julamanee J, Watanabe K, Hamana H, et al. Introduction of genetically modified CD3\u03b6 improves proliferation and persistence of antigen-specific CTLs. Cancer Immunol Res. 2018;6(6):733\u201344.","journal-title":"Cancer Immunol Res"},{"issue":"4","key":"793_CR94","doi-asserted-by":"publisher","first-page":"e005519","DOI":"10.1136\/jitc-2022-005519","volume":"11","author":"S Lah","year":"2023","unstructured":"Lah S, Kim S, Kang I, Kim H, Hupperetz C, Jung H, et al. Engineering second-generation TCR-T cells by site-specific integration of TRAF-binding motifs into theCD247locus. J Immunother Cancer. 2023;11(4):e005519.","journal-title":"J Immunother Cancer"},{"issue":"1","key":"793_CR95","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1158\/2326-6066.CIR-21-1118","volume":"11","author":"W Liang","year":"2023","unstructured":"Liang W, Yi R, Wang W, Shi Y, Zhang J, Xu X, et al. Enhancing the antitumor immunity of T cells by engineering the lipid-regulatory site of the TCR\/CD3 complex. Cancer Immunol Res. 2023;11(1):93\u2013108.","journal-title":"Cancer Immunol Res"},{"issue":"8","key":"793_CR96","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.3390\/cancers14081998","volume":"14","author":"N Sailer","year":"2022","unstructured":"Sailer N, Fetzer I, Salvermoser M, Braun M, Brechtefeld D, Krendl C, et al. T-cells expressing a highly potent PRAME-specific T-cell receptor in combination with a chimeric PD1-41BB co-stimulatory receptor show a favorable preclinical safety profile and strong anti-tumor reactivity. Cancers. 2022;14(8):1998.","journal-title":"Cancers"},{"issue":"5","key":"793_CR97","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1016\/j.chembiol.2024.04.005","volume":"31","author":"Z Ren","year":"2024","unstructured":"Ren Z, Wang K, Zhang Y, Chen H, Zhu Y, Li H, et al. Transient hydroxycholesterol treatment restrains TCR signaling to promote long-term immunity. Cell Chem Biol. 2024;31(5):920-31.e6.","journal-title":"Cell Chem Biol"},{"key":"793_CR98","doi-asserted-by":"publisher","first-page":"1114770","DOI":"10.3389\/fimmu.2023.1114770","volume":"14","author":"MS Hussein","year":"2023","unstructured":"Hussein MS, Li Q, Mao R, Peng Y, He Y. TCR T cells overexpressing c-Jun have better functionality with improved tumor infiltration and persistence in hepatocellular carcinoma. Front Immunol. 2023;14:1114770.","journal-title":"Front Immunol"},{"issue":"8","key":"793_CR99","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1007\/s00262-024-03729-y","volume":"73","author":"M Shen","year":"2024","unstructured":"Shen M, Chen S, Han X, Hao Y, Wang J, Li L, et al. Identification of an HLA-A*11:01-restricted neoepitope of mutant PIK3CA and its specific T cell receptors for cancer immunotherapy targeting hotspot driver mutations. Cancer Immunol Immunother. 2024;73(8):150.","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"793_CR100","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s12943-023-01844-5","volume":"22","author":"J Li","year":"2023","unstructured":"Li J, Xiao Z, Wang D, Jia L, Nie S, Zeng X, et al. The screening, identification, design and clinical application of tumor-specific neoantigens for TCR-T cells. Mol Cancer. 2023;22(1):141.","journal-title":"Mol Cancer"},{"issue":"6","key":"793_CR101","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/j.stem.2018.10.005","volume":"23","author":"A Minagawa","year":"2018","unstructured":"Minagawa A, Yoshikawa T, Yasukawa M, Hotta A, Kunitomo M, Iriguchi S, et al. Enhancing T cell receptor stability in rejuvenated iPSC-derived T cells improves their use in cancer immunotherapy. Cell Stem Cell. 2018;23(6):850-8.e4.","journal-title":"Cell Stem Cell"},{"issue":"12","key":"793_CR102","doi-asserted-by":"publisher","first-page":"3473","DOI":"10.1158\/0008-5472.CAN-15-1742","volume":"76","author":"H Saito","year":"2016","unstructured":"Saito H, Okita K, Chang AE, Ito F. Adoptive transfer of CD8+ T cells generated from induced pluripotent stem cells triggers regressions of large tumors along with immunological memory. Cancer Res. 2016;76(12):3473\u201383.","journal-title":"Cancer Res"},{"key":"793_CR103","doi-asserted-by":"publisher","first-page":"107848","DOI":"10.1016\/j.intimp.2021.107848","volume":"98","author":"S Chen","year":"2021","unstructured":"Chen S, Zhang J, Shen M, Han X, Li S, Hu C, et al. p38 inhibition enhances TCR-T cell function and antagonizes the immunosuppressive activity of TGF-\u03b2. Int Immunopharmacol. 2021;98:107848.","journal-title":"Int Immunopharmacol"},{"issue":"1","key":"793_CR104","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1158\/1535-7163.MCT-21-0400","volume":"21","author":"Y Tokunaga","year":"2022","unstructured":"Tokunaga Y, Sasaki T, Goto S, Adachi K, Sakoda Y, Tamada K. Enhanced antitumor responses of tumor antigen-specific TCR T cells genetically engineered to produce IL7 and CCL19. Mol Cancer Ther. 2022;21(1):138\u201348.","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"793_CR105","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41392-024-01792-6","volume":"9","author":"W Zhu","year":"2024","unstructured":"Zhu W, Zhang Z, Chen J, Chen X, Huang L, Zhang X, et al. A novel engineered IL-21 receptor arms T-cell receptor-engineered T cells (TCR-T cells) against hepatocellular carcinoma. Signal Transduct Target Ther. 2024;9(1):101.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"793_CR106","doi-asserted-by":"publisher","first-page":"e000210","DOI":"10.1136\/jitc-2019-000210","volume":"8","author":"L Zhang","year":"2020","unstructured":"Zhang L, Davies JS, Serna C, Yu Z, Restifo NP, Rosenberg SA, et al. Enhanced efficacy and limited systemic cytokine exposure with membrane-anchored interleukin-12 T-cell therapy in murine tumor models. J Immunother Cancer. 2020;8(1):e000210.","journal-title":"J Immunother Cancer"},{"issue":"1","key":"793_CR107","doi-asserted-by":"publisher","first-page":"e003633","DOI":"10.1136\/jitc-2021-003633","volume":"10","author":"J Hu","year":"2022","unstructured":"Hu J, Yang Q, Zhang W, Du H, Chen Y, Zhao Q, et al. Cell membrane-anchored and tumor-targeted IL-12 (attIL12)-T cell therapy for eliminating large and heterogeneous solid tumors. J Immunother Cancer. 2022;10(1):e003633.","journal-title":"J Immunother Cancer"},{"key":"793_CR108","doi-asserted-by":"publisher","first-page":"1062365","DOI":"10.3389\/fimmu.2023.1062365","volume":"14","author":"S Kim","year":"2023","unstructured":"Kim S, Park CI, Lee S, Choi HR, Kim CH. Reprogramming of IL-12 secretion in the PDCD1 locus improves the anti-tumor activity of NY-ESO-1 TCR-T cells. Front Immunol. 2023;14:1062365.","journal-title":"Front Immunol"},{"issue":"8","key":"793_CR109","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1158\/1078-0432.CCR-23-1872","volume":"30","author":"R Nguyen","year":"2024","unstructured":"Nguyen R, Doubrovina E, Mousset CM, Jin BY, Okada R, Zhang X, et al. Cooperative armoring of CAR and TCR T cells by T cell-restricted IL15 and IL21 universally enhances solid tumor efficacy. Clin Cancer Res. 2024;30(8):1555\u201366.","journal-title":"Clin Cancer Res"},{"issue":"10","key":"793_CR110","doi-asserted-by":"publisher","first-page":"3942","DOI":"10.7150\/ijbs.93668","volume":"20","author":"W Xu","year":"2024","unstructured":"Xu W, Hu M, Lu X, Lao Y, Ma N, Wang Y, et al. Inhibition of PCSK9 enhances the anti-hepatocellular carcinoma effects of TCR-T cells and anti-PD-1 immunotherapy. Int J Biol Sci. 2024;20(10):3942\u201355.","journal-title":"Int J Biol Sci"},{"issue":"1","key":"793_CR111","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s12935-024-03249-w","volume":"24","author":"OB Amissah","year":"2024","unstructured":"Amissah OB, Chen W, de Dieu HJ, Sun Y, Lin L, Liu Y, et al. NY-ESO-1-specific T cell receptor-engineered T cells and Tranilast, a TRPV2 antagonist bivalent treatment enhances the killing of esophageal cancer: a dual-targeted cancer therapeutic route. Cancer Cell Int. 2024;24(1):64.","journal-title":"Cancer Cell Int"},{"key":"793_CR112","doi-asserted-by":"publisher","first-page":"104863","DOI":"10.1016\/j.cellimm.2024.104863","volume":"403","author":"J Wang","year":"2024","unstructured":"Wang J, Han X, Hao Y, Chen S, Pang B, Zou L, et al. Cbl-b inhibition promotes less differentiated phenotypes of T cells with enhanced cytokine production. Cellular Immunol. 2024;403:104863.","journal-title":"Cellular Immunol"},{"issue":"1","key":"793_CR113","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s40164-024-00575-7","volume":"13","author":"Z Zhou","year":"2024","unstructured":"Zhou Z, Zheng J, Lu Y, Mai Z, Lin Y, Lin P, et al. Optimizing CD8 (+) T cell-based immunotherapy via metabolic interventions: a comprehensive review of intrinsic and extrinsic modulators. Exp Hematol Oncol. 2024;13(1):103.","journal-title":"Exp Hematol Oncol"},{"issue":"1","key":"793_CR114","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s40164-024-00535-1","volume":"13","author":"A Van der Vreken","year":"2024","unstructured":"Van der Vreken A, Vanderkerken K, De Bruyne E, De Veirman K, Breckpot K, Menu E. Fueling CARs: metabolic strategies to enhance CAR T-cell therapy. Exp Hematol Oncol. 2024;13(1):66.","journal-title":"Exp Hematol Oncol"},{"issue":"12","key":"793_CR115","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1016\/j.cels.2024.11.010","volume":"15","author":"B Feng","year":"2024","unstructured":"Feng B, Li R, Li W, Tang L. Metabolic immunoengineering approaches to enhance CD8+ T cell-based cancer immunotherapy. Cell Syst. 2024;15(12):1225\u201344.","journal-title":"Cell Syst"},{"issue":"762","key":"793_CR116","doi-asserted-by":"publisher","first-page":"7399","DOI":"10.1126\/scitranslmed.adk7399","volume":"16","author":"Y Liu","year":"2024","unstructured":"Liu Y, Wang F, Peng D, Zhang D, Liu L, Wei J, et al. Activation and antitumor immunity of CD8 (+) T cells are supported by the glucose transporter GLUT10 and disrupted by lactic acid. Sci Transl Med. 2024;16(762):7399.","journal-title":"Sci Transl Med"},{"issue":"12","key":"793_CR117","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1038\/s41590-024-01999-3","volume":"25","author":"RM Peralta","year":"2024","unstructured":"Peralta RM, Xie B, Lontos K, Nieves-Rosado H, Spahr K, Joshi S, et al. Dysfunction of exhausted T cells is enforced by MCT11-mediated lactate metabolism. Nat Immunol. 2024;25(12):2297\u2013307.","journal-title":"Nat Immunol"},{"issue":"1","key":"793_CR118","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.ccell.2024.11.003","volume":"43","author":"Y Qiu","year":"2025","unstructured":"Qiu Y, Su Y, Xie E, Cheng H, Du J, Xu Y, et al. Mannose metabolism reshapes T cell differentiation to enhance anti-tumor immunity. Cancer Cell. 2025;43(1):103-21.e8.","journal-title":"Cancer Cell"},{"issue":"1","key":"793_CR119","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1186\/s12964-024-01848-8","volume":"22","author":"W Zhou","year":"2024","unstructured":"Zhou W, Qu M, Yue Y, Zhong Z, Nan K, Sun X, et al. Acetylcysteine synergizes PD-1 blockers against colorectal cancer progression by promoting TCF1+PD1+CD8+ T cell differentiation. Cell Commun Signal. 2024;22(1):503.","journal-title":"Cell Commun Signal"},{"issue":"1","key":"793_CR120","doi-asserted-by":"publisher","first-page":"7366","DOI":"10.1038\/s41467-024-51500-9","volume":"15","author":"I Pallavicini","year":"2024","unstructured":"Pallavicini I, Frasconi TM, Catozzi C, Ceccacci E, Tiberti S, Haas D, et al. LSD1 inhibition improves efficacy of adoptive T cell therapy by enhancing CD8+ T cell responsiveness. Nat Commun. 2024;15(1):7366.","journal-title":"Nat Commun"},{"issue":"2","key":"793_CR121","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.ccell.2024.12.001","volume":"43","author":"S Ma","year":"2025","unstructured":"Ma S, Ong L-T, Jiang Z, Lee WC, Lee PL, Yusuf M, et al. Targeting P4HA1 promotes CD8+ T cell progenitor expansion toward immune memory and systemic anti-tumor immunity. Cancer Cell. 2025;43(2):213-31.e9.","journal-title":"Cancer Cell"},{"issue":"1","key":"793_CR122","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1186\/s40164-025-00705-9","volume":"14","author":"Y Wang","year":"2025","unstructured":"Wang Y, Jiang C, Zhou H, Han R. Transforming cancer immunotherapy: integration of distinct immune-based approaches as redefined dual immunotherapy with potential third-sensitizer. Exp Hematol Oncol. 2025;14(1):114.","journal-title":"Exp Hematol Oncol"},{"issue":"9","key":"793_CR123","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1016\/j.ccell.2022.08.001","volume":"40","author":"N Zheng","year":"2022","unstructured":"Zheng N, Fang J, Xue G, Wang Z, Li X, Zhou M, et al. Induction of tumor cell autosis by myxoma virus-infected CAR-T and TCR-T cells to overcome primary and acquired resistance. Cancer Cell. 2022;40(9):973-85.e7.","journal-title":"Cancer Cell"},{"issue":"2","key":"793_CR124","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1158\/2326-6066.CIR-22-0978","volume":"12","author":"DJ Drakes","year":"2024","unstructured":"Drakes DJ, Abbas AM, Shields J, Steinbuck MP, Jakubowski A, Seenappa LM, et al. Lymph node-targeted vaccine boosting of TCR T-cell therapy enhances antitumor function and eradicates solid tumors. Cancer Immunol Res. 2024;12(2):214\u201331.","journal-title":"Cancer Immunol Res"},{"issue":"11","key":"793_CR125","doi-asserted-by":"publisher","first-page":"e161660","DOI":"10.1172\/JCI161660","volume":"134","author":"E Stefanidis","year":"2024","unstructured":"Stefanidis E, Semilietof A, Pujol J, Seijo B, Scholten K, Zoete V, et al. Combining SiRP\u03b1 decoy-coengineered T cells and antibodies augments macrophage-mediated phagocytosis of tumor cells. J Clin Invest. 2024;134(11):e161660.","journal-title":"J Clin Invest"},{"key":"793_CR126","doi-asserted-by":"crossref","unstructured":"Wang X, Yang X, Wang Y, Chen Y, Yang Y, Shang S, et al. Combination of expanded allogeneic NK cells and T cell-based immunotherapy exert enhanced antitumor effects. Cancers. 2022;15 (1).","DOI":"10.3390\/cancers15010251"},{"issue":"12","key":"793_CR127","doi-asserted-by":"publisher","first-page":"2450","DOI":"10.1158\/2159-8290.CD-24-0168","volume":"14","author":"D Kortleve","year":"2024","unstructured":"Kortleve D, Hammerl D, van Brakel M, Wijers R, Roelofs D, Kroese K, et al. TCR-engineered T cells directed against Ropporin-1 constitute a safe and effective treatment for triple-negative breast cancer. Cancer Discov. 2024;14(12):2450\u201370.","journal-title":"Cancer Discov"},{"key":"793_CR128","doi-asserted-by":"publisher","first-page":"1121973","DOI":"10.3389\/fimmu.2023.1121973","volume":"14","author":"RA van Amerongen","year":"2023","unstructured":"van Amerongen RA, Tuit S, Wouters AK, van de Meent M, Siekman SL, Meeuwsen MH, et al. PRAME and CTCFL-reactive TCRs for the treatment of ovarian cancer. Front Immunol. 2023;14:1121973.","journal-title":"Front Immunol"},{"issue":"8","key":"793_CR129","doi-asserted-by":"publisher","first-page":"e99488","DOI":"10.1172\/jci.insight.99488","volume":"3","author":"BY Jin","year":"2018","unstructured":"Jin BY, Campbell TE, Draper LM, Stevanovi\u0107 S, Weissbrich B, Yu Z, et al. Engineered T cells targeting E7 mediate regression of human papillomavirus cancers in a murine model. JCI Insight. 2018;3(8):e99488.","journal-title":"JCI Insight"},{"key":"793_CR130","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.molimm.2024.05.006","volume":"171","author":"X Li","year":"2024","unstructured":"Li X, Wang W, Wang J, Jiang M, He J, Tan S. Identification of HPV-E7 specific TCRs for tumor immunotherapy. Mol Immunol. 2024;171:56\u201365.","journal-title":"Mol Immunol"},{"key":"793_CR131","doi-asserted-by":"publisher","first-page":"644520","DOI":"10.3389\/fimmu.2021.644520","volume":"12","author":"H Zhang","year":"2021","unstructured":"Zhang H, Sun M, Wang J, Zeng B, Cao X, Han Y, et al. Identification of NY-ESO-1157\u2013165 specific murine T cell receptors with distinct recognition pattern for tumor immunotherapy. Front Immunol. 2021;12:644520.","journal-title":"Front Immunol"},{"issue":"6","key":"793_CR132","doi-asserted-by":"publisher","first-page":"e10585","DOI":"10.1002\/btm2.10585","volume":"8","author":"R Xu","year":"2023","unstructured":"Xu R, Wang Q, Zhu J, Bei Y, Chu Y, Sun Z, et al. Membrane fusogenic nanoparticle-based HLA-peptide-addressing universal T cell receptor-engineered T (HAUL TCR-T) cell therapy in solid tumor. Bioeng Transl Med. 2023;8(6):e10585.","journal-title":"Bioeng Transl Med"},{"issue":"7","key":"793_CR133","doi-asserted-by":"publisher","first-page":"e618","DOI":"10.1002\/mco2.618","volume":"5","author":"Q Wang","year":"2024","unstructured":"Wang Q, Peng R, Qi H, Xu R, Liu W, Meng F, et al. Liposome-based in situ antigen-modification strategy for \u201cuniversal\u201d T-cell-receptor engineered T cell in cancer immunotherapy. MedComm. 2024;5(7):e618.","journal-title":"MedComm"},{"issue":"1","key":"793_CR134","doi-asserted-by":"publisher","first-page":"6389","DOI":"10.1038\/s41467-023-42010-1","volume":"14","author":"D Lu","year":"2023","unstructured":"Lu D, Chen Y, Jiang M, Wang J, Li Y, Ma K, et al. KRAS G12V neoantigen specific T cell receptor for adoptive T cell therapy against tumors. Nat Commun. 2023;14(1):6389.","journal-title":"Nat Commun"},{"issue":"4","key":"793_CR135","doi-asserted-by":"publisher","first-page":"e008967","DOI":"10.1136\/jitc-2024-008967","volume":"12","author":"X Long","year":"2024","unstructured":"Long X, Zhang Z, Li Y, Deng K, Gao W, Huang M, et al. ScRNA-seq reveals novel immune-suppressive T cells and investigates CMV-TCR-T cells cytotoxicity against GBM. J Immunother Cancer. 2024;12(4):e008967.","journal-title":"J Immunother Cancer"},{"key":"793_CR136","doi-asserted-by":"publisher","first-page":"216366","DOI":"10.1016\/j.canlet.2023.216366","volume":"573","author":"J Wang","year":"2023","unstructured":"Wang J, Zhang T, Li P, Gai J, Chen S, Espinoza G, et al. Engineered TCR T-cell therapy targeting mass spectrometry-identified natural epitope in PDAC. Cancer Lett. 2023;573:216366.","journal-title":"Cancer Lett"},{"issue":"2","key":"793_CR137","doi-asserted-by":"publisher","first-page":"e001748","DOI":"10.1136\/jitc-2020-001748","volume":"8","author":"Q Liu","year":"2020","unstructured":"Liu Q, Tian Y, Li Y, Zhang W, Cai W, Liu Y, et al. In vivo therapeutic effects of affinity-improved-TCR engineered T-cells on HBV-related hepatocellular carcinoma. J Immunother Cancer. 2020;8(2):e001748.","journal-title":"J Immunother Cancer"},{"issue":"2","key":"793_CR138","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1097\/HEP.0000000000001175","volume":"82","author":"E Vercher","year":"2024","unstructured":"Vercher E, Covo-Vergara \u00c1, Conde E, Hern\u00e1ndez-Rueda M, Elizalde E, Manche\u00f1o U, et al. Human T cells engineered with an HLA-A2-restricted murine T-cell receptor targeting glypican 3 effectively control human hepatocellular carcinoma in mice. Hepatology. 2024;82(2):326\u201343.","journal-title":"Hepatology"},{"key":"793_CR139","doi-asserted-by":"publisher","first-page":"107209","DOI":"10.1016\/j.phrs.2024.107209","volume":"204","author":"P Yao","year":"2024","unstructured":"Yao P, Gao M, Hu W, Wang J, Wang Y, Wang Q, et al. Proteogenomic analysis identifies neoantigens and bacterial peptides as immunotherapy targets in colorectal cancer. Pharmacol Res. 2024;204:107209.","journal-title":"Pharmacol Res"},{"issue":"3","key":"793_CR140","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1016\/j.ymthe.2020.11.019","volume":"29","author":"P Dillard","year":"2021","unstructured":"Dillard P, K\u00f6ksal H, Maggadottir SM, Winge-Main A, Pollmann S, Menard M, et al. Targeting telomerase with an HLA Class II-restricted TCR for cancer immunotherapy. Mol Ther. 2021;29(3):1199\u2013213.","journal-title":"Mol Ther"},{"issue":"8","key":"793_CR141","doi-asserted-by":"publisher","first-page":"e172092","DOI":"10.1172\/JCI172092","volume":"134","author":"C Wang","year":"2024","unstructured":"Wang C, Chen J, Li J, Xu Z, Huang L, Zhao Q, et al. An EBV-related CD4 TCR immunotherapy inhibits tumor growth in an HLA-DP5+ nasopharyngeal cancer mouse model. J Clin Invest. 2024;134(8):e172092.","journal-title":"J Clin Invest"},{"key":"793_CR142","doi-asserted-by":"publisher","first-page":"939940","DOI":"10.3389\/fimmu.2022.939940","volume":"13","author":"Y Liang","year":"2022","unstructured":"Liang Y, Xu Q, Liu S, Li J, Wang F, Li Z, et al. Single-Cell Transcriptomics Reveals Killing Mechanisms of Antitumor Cytotoxic CD4+ TCR-T Cells. Front Immunol. 2022;13:939940.","journal-title":"Front Immunol"},{"issue":"74","key":"793_CR143","doi-asserted-by":"publisher","first-page":"eabn6563","DOI":"10.1126\/sciimmunol.abn6563","volume":"7","author":"G Delfanti","year":"2022","unstructured":"Delfanti G, Cortesi F, Perini A, Antonini G, Azzimonti L, de Lalla C, et al. TCR-engineered iNKT cells induce robust antitumor response by dual tar geting cancer and suppressive myeloid cells. Sci Immunol. 2022;7(74):eabn6563.","journal-title":"Sci Immunol"},{"issue":"9","key":"793_CR144","doi-asserted-by":"publisher","first-page":"102321","DOI":"10.1016\/j.xcrm.2025.102321","volume":"6","author":"Y-R Li","year":"2025","unstructured":"Li Y-R, Hu J, Li Z, Zhu E, Chen Y, Halladay T, et al. Multimodal targeting of metastatic renal cell carcinoma via CD70-directed allogeneic CAR-NKT cells. Cell Rep Med. 2025;6(9):102321.","journal-title":"Cell Rep Med"},{"issue":"10","key":"793_CR145","doi-asserted-by":"publisher","first-page":"100804","DOI":"10.1016\/j.medj.2025.100804","volume":"6","author":"Y-R Li","year":"2025","unstructured":"Li Y-R, Li Z, Zhu Y, Li M, Chen Y, Lee D, et al. Overcoming ovarian cancer resistance and evasion to CAR-T cell therapy by harnessing allogeneic CAR-NKT cells. Med. 2025;6(10):100804.","journal-title":"Med"},{"key":"793_CR146","doi-asserted-by":"publisher","first-page":"895103","DOI":"10.3389\/fonc.2022.895103","volume":"12","author":"G Yu","year":"2022","unstructured":"Yu G, Wang W, He X, Xu J, Xu R, Wan T, et al. Synergistic therapeutic effects of low dose decitabine and NY-ESO-1 specific TCR-T cells for the colorectal cancer with microsatellite stability. Front Oncol. 2022;12:895103.","journal-title":"Front Oncol"},{"issue":"12","key":"793_CR147","doi-asserted-by":"publisher","first-page":"4511","DOI":"10.1111\/cas.15986","volume":"114","author":"A Wada","year":"2023","unstructured":"Wada A, Hirohashi Y, Kutomi G, Murata K, Iwabuchi S, Mizue Y, et al. Eribulin is an immune potentiator in breast cancer that upregulates human leukocyte antigen class I expression via the induction of NOD-like receptor family CARD domain-containing 5. Cancer Sci. 2023;114(12):4511\u201320.","journal-title":"Cancer Sci"},{"issue":"3","key":"793_CR148","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s00262-024-03628-2","volume":"73","author":"A Chen","year":"2024","unstructured":"Chen A, Yu Z, Ma N, Lu X, Zhang Y, Xu W, et al. Atovaquone enhances antitumor efficacy of TCR-T therapy by augmentation of ROS-induced ferroptosis in hepatocellular carcinoma. Cancer Immunol Immunother. 2024;73(3):49.","journal-title":"Cancer Immunol Immunother"},{"issue":"4","key":"793_CR149","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/s41419-024-06638-1","volume":"15","author":"L Wang","year":"2024","unstructured":"Wang L, Liang Z, Guo Y, Habimana JDD, Ren Y, Amissah OB, et al. STING agonist diABZI enhances the cytotoxicity of T cell towards cancer cells. Cell Death Disease. 2024;15(4):265.","journal-title":"Cell Death Disease"},{"issue":"7","key":"793_CR150","doi-asserted-by":"publisher","first-page":"2132","DOI":"10.1016\/j.ymthe.2023.05.009","volume":"31","author":"B Cieniewicz","year":"2023","unstructured":"Cieniewicz B, Bhatta A, Torabi D, Baichoo P, Saxton M, Arballo A, et al. Chimeric TIM-4 receptor-modified T cells targeting phosphatidylserine mediates both cytotoxic anti-tumor responses and phagocytic uptake of tumor-associated antigen for T cell cross-presentation. Mol Ther. 2023;31(7):2132\u201353.","journal-title":"Mol Ther"},{"issue":"1","key":"793_CR151","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1002\/hep.31662","volume":"74","author":"M Hafezi","year":"2021","unstructured":"Hafezi M, Lin M, Chia A, Chua A, Ho ZZ, Fam R, et al. Immunosuppressive drug-resistant armored T-cell receptor T cells for immune therapy of HCC in liver transplant patients. Hepatology. 2021;74(1):200\u201313.","journal-title":"Hepatology"},{"issue":"4","key":"793_CR152","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1002\/hep4.1857","volume":"6","author":"AT Tan","year":"2021","unstructured":"Tan AT, Meng F, Jin J, Zhang JY, Wang SY, Shi L, et al. Immunological alterations after immunotherapy with short lived HBV-TCR T cells associates with long-term treatment response in HBV-HCC. Hepatol Commun. 2021;6(4):841\u201354.","journal-title":"Hepatol Commun"},{"issue":"1","key":"793_CR153","doi-asserted-by":"publisher","first-page":"015","DOI":"10.1093\/immadv\/ltad015","volume":"3","author":"M Lin","year":"2023","unstructured":"Lin M, Bhakdi SC, Tan D, Lee JJX, Tai DWM, Pavesi A, et al. Lytic efficiency of immunosuppressive drug-resistant armoured T cells against circulating HBV-related HCC in whole blood. Immunother Adv. 2023;3(1):015.","journal-title":"Immunother Adv"},{"key":"793_CR154","doi-asserted-by":"publisher","first-page":"1148890","DOI":"10.3389\/fimmu.2023.1148890","volume":"14","author":"A Degirmencay","year":"2023","unstructured":"Degirmencay A, Thomas S, Mohammed F, Willcox BE, Stauss HJ. Modifications outside CDR1, 2 and 3 of the TCR variable \u03b2 domain increase TCR expression and antigen-specific function. Front Immunol. 2023;14:1148890.","journal-title":"Front Immunol"},{"issue":"12","key":"793_CR155","doi-asserted-by":"publisher","first-page":"3337","DOI":"10.1158\/0008-5472.CAN-17-3140","volume":"78","author":"D Orlando","year":"2018","unstructured":"Orlando D, Miele E, De Angelis B, Guercio M, Boffa I, Sinibaldi M, et al. Adoptive immunotherapy using prame-specific T cells in medulloblastoma. Can Res. 2018;78(12):3337\u201349.","journal-title":"Can Res"},{"issue":"6","key":"793_CR156","doi-asserted-by":"publisher","first-page":"e406","DOI":"10.1093\/oncolo\/oyad078","volume":"28","author":"R Yarza","year":"2023","unstructured":"Yarza R, Bover M, Herrera-Juarez M, Rey-Cardenas M, Paz-Ares L, Lopez-Martin JA, et al. Efficacy of T-cell receptor-based adoptive cell therapy in cutaneous melanoma: a meta-analysis. Oncologist. 2023;28(6):e406\u201315.","journal-title":"Oncologist"},{"key":"793_CR157","doi-asserted-by":"publisher","first-page":"818679","DOI":"10.3389\/fonc.2022.818679","volume":"12","author":"DS Hong","year":"2022","unstructured":"Hong DS, Butler MO, Pachynski RK, Sullivan R, Kebriaei P, Boross-Harmer S, et al. Phase 1 clinical trial evaluating the safety and anti-tumor activity of ADP-A2M10 SPEAR T-cells in patients with MAGE-A10+ head and neck, melanoma, or urothelial tumors. Front Oncol. 2022;12:818679.","journal-title":"Front Oncol"},{"issue":"1","key":"793_CR158","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41591-022-02128-z","volume":"29","author":"DS Hong","year":"2023","unstructured":"Hong DS, Van Tine BA, Biswas S, McAlpine C, Johnson ML, Olszanski AJ, et al. Autologous T cell therapy for MAGE-A4+ solid cancers in HLA-A*02+ patients: a phase 1 trial. Nat Med. 2023;29(1):104\u201314.","journal-title":"Nat Med"},{"issue":"8","key":"793_CR159","doi-asserted-by":"publisher","first-page":"101133","DOI":"10.1016\/j.xcrm.2023.101133","volume":"4","author":"Q Pan","year":"2023","unstructured":"Pan Q, Weng D, Liu J, Han Z, Ou Y, Xu B, et al. Phase 1 clinical trial to assess safety and efficacy of NY-ESO-1-specific TCR T cells in HLA-A\u221702:01 patients with advanced soft tissue sarcoma. Cell Rep Med. 2023;4(8):101133.","journal-title":"Cell Rep Med"},{"issue":"16_suppl","key":"793_CR160","doi-asserted-by":"publisher","first-page":"2500","DOI":"10.1200\/JCO.2024.42.16_suppl.2500","volume":"42","author":"SP D'Angelo","year":"2024","unstructured":"D\u2019Angelo SP, Furness AJS, Thistlethwaite F, Burgess MA, Riedel RF, Haanen J, et al. Lete-cel in patients with synovial sarcoma or myxoid\/round cell liposarcoma: planned interim analysis of the pivotal IGNYTE-ESO trial. J Clin Oncol. 2024;42(16_suppl):2500.","journal-title":"J Clin Oncol"},{"issue":"6","key":"793_CR161","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1007\/s12072-021-10250-2","volume":"15","author":"F Meng","year":"2021","unstructured":"Meng F, Zhao J, Tan AT, Hu W, Wang S-Y, Jin J, et al. Immunotherapy of HBV-related advanced hepatocellular carcinoma with short-term HBV-specific TCR expressed T cells: results of dose escalation, phase I trial. Hep Intl. 2021;15(6):1402\u201312.","journal-title":"Hep Intl"},{"issue":"4","key":"793_CR162","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1007\/s12072-023-10524-x","volume":"17","author":"F Yang","year":"2023","unstructured":"Yang F, Zheng X, Koh S, Lu J, Cheng J, Li P, et al. Messenger RNA electroporated hepatitis B virus (HBV) antigen-specific T cell receptor (TCR) redirected T cell therapy is well-tolerated in patients with recurrent HBV-related hepatocellular carcinoma post-liver transplantation: results from a phase I trial. Hepatol Int. 2023;17(4):850\u20139.","journal-title":"Hepatol Int"},{"issue":"2","key":"793_CR163","doi-asserted-by":"publisher","first-page":"101265","DOI":"10.1016\/j.omtm.2024.101265","volume":"32","author":"T Wang","year":"2024","unstructured":"Wang T, Navenot J-M, Rafail S, Kurtis C, Carroll M, Van Kerckhoven M, et al. Identifying MAGE-A4-positive tumors for TCR T cell therapies in HLA-A\u221702-eligible patients. Mol Ther Methods Clin Develop. 2024;32(2):101265.","journal-title":"Mol Ther Methods Clin Develop"},{"issue":"22","key":"793_CR164","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1056\/NEJMoa2119662","volume":"386","author":"R Leidner","year":"2022","unstructured":"Leidner R, Sanjuan Silva N, Huang H, Sprott D, Zheng C, Shih Y-P, et al. Neoantigen T-cell receptor gene therapy in pancreatic cancer. N Engl J Med. 2022;386(22):2112\u20139.","journal-title":"N Engl J Med"},{"issue":"8","key":"793_CR165","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1158\/2326-6066.CIR-22-0040","volume":"10","author":"SP Kim","year":"2022","unstructured":"Kim SP, Vale NR, Zacharakis N, Krishna S, Yu Z, Gasmi B, et al. Adoptive cellular therapy with autologous tumor-infiltrating lymphocytes and T-cell receptor-engineered T cells targeting common p53 neoantigens in human solid tumors. Cancer Immunol Res. 2022;10(8):932\u201346.","journal-title":"Cancer Immunol Res"},{"issue":"4","key":"793_CR166","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1007\/s00262-022-03287-1","volume":"72","author":"K Owen","year":"2022","unstructured":"Owen K, Ghaly R, Shohdy KS, Thistlethwaite F. Lymphodepleting chemotherapy practices and effect on safety and efficacy outcomes in patients with solid tumours undergoing T cell receptor-engineered T cell (TCR-T) therapy: a systematic review and meta-analysis. Cancer Immunol Immunother. 2022;72(4):805\u201314.","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"793_CR167","doi-asserted-by":"publisher","first-page":"5296","DOI":"10.1038\/s41467-022-32491-x","volume":"13","author":"A Gyurdieva","year":"2022","unstructured":"Gyurdieva A, Zajic S, Chang Y-F, Houseman EA, Zhong S, Kim J, et al. Biomarker correlates with response to NY-ESO-1 TCR T cells in patients with synovial sarcoma. Nat Commun. 2022;13(1):5296.","journal-title":"Nat Commun"},{"issue":"1","key":"793_CR168","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1186\/s40425-019-0762-2","volume":"7","author":"I Ramachandran","year":"2019","unstructured":"Ramachandran I, Lowther DE, Dryer-Minnerly R, Wang R, Fayngerts S, Nunez D, et al. Systemic and local immunity following adoptive transfer of NY-ESO-1 SPEAR T cells in synovial sarcoma. J Immunother Cancer. 2019;7(1):276.","journal-title":"J Immunother Cancer"},{"issue":"7","key":"793_CR169","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.1158\/1078-0432.CCR-18-3496","volume":"25","author":"TS Nowicki","year":"2019","unstructured":"Nowicki TS, Berent-Maoz B, Cheung-Lau G, Huang RR, Wang X, Tsoi J, et al. A pilot trial of the combination of transgenic NY-ESO-1-reactive adoptive cellular therapy with dendritic cell vaccination with or without Ipilimumab. Clin Cancer Res. 2019;25(7):2096\u2013108.","journal-title":"Clin Cancer Res"},{"issue":"12","key":"793_CR170","doi-asserted-by":"publisher","first-page":"2554","DOI":"10.1002\/ijc.34453","volume":"152","author":"M Ishihara","year":"2023","unstructured":"Ishihara M, Nishida Y, Kitano S, Kawai A, Muraoka D, Momose F, et al. A phase 1 trial of NY\u2010ESO\u20101\u2010specific TCR\u2010engineered T\u2010cell therapy combined with a lymph node\u2010targeting nanoparticulate peptide vaccine for the treatment of advanced soft tissue sarcoma. Int J Cancer. 2023;152(12):2554\u201366.","journal-title":"Int J Cancer"},{"issue":"4","key":"793_CR171","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1097\/CMR.0000000000000869","volume":"33","author":"K He","year":"2023","unstructured":"He K, Hong DS, Ke D, Kebriaei P, Wang T, Danesi H, et al. Durable control of metastases in an HLA-A2+ patient with refractory melanoma after low-dose radiotherapy in combination with MAGE-A4 T cell therapy: a case report. Melanoma Res. 2023;33(4):332\u20137.","journal-title":"Melanoma Res"},{"issue":"10","key":"793_CR172","doi-asserted-by":"publisher","first-page":"4957","DOI":"10.7150\/thno.55075","volume":"11","author":"R Ding","year":"2021","unstructured":"Ding R, Liu S, Wang S, Chen H, Wang F, Xu Q, et al. Single-cell transcriptome analysis of the heterogeneous effects of differential expression of tumor PD-L1 on responding TCR-T cells. Theranostics. 2021;11(10):4957\u201374.","journal-title":"Theranostics"},{"issue":"11","key":"793_CR173","doi-asserted-by":"publisher","first-page":"4865","DOI":"10.1182\/blood-2006-09-045245","volume":"109","author":"L-X Wang","year":"2007","unstructured":"Wang L-X, Shu S, Disis ML, Plautz GE. Adoptive transfer of tumor-primed, in vitro\u2013activated, CD4+ T effector cells (TEs) combined with CD8+ TEs provides intratumoral TE proliferation and synergistic antitumor response. Blood. 2007;109(11):4865\u201376.","journal-title":"Blood"},{"key":"793_CR174","doi-asserted-by":"publisher","first-page":"1202017","DOI":"10.3389\/fimmu.2024.1202017","volume":"15","author":"P Mercier-Letondal","year":"2024","unstructured":"Mercier-Letondal P, Kumar A, Marton C, Bonnefoy F, Fredon M, Boullerot L, et al. Characterization of atypical T cells generated during ex vivo expansion process for T cell-based adoptive immunotherapy. Front Immunol. 2024;15:1202017.","journal-title":"Front Immunol"},{"issue":"9","key":"793_CR175","doi-asserted-by":"publisher","first-page":"e009376","DOI":"10.1136\/jitc-2024-009376","volume":"12","author":"Q Peng","year":"2024","unstructured":"Peng Q, Xu Y, Yao X. scRNA+ TCR-seq revealed dual TCR T cells antitumor response in the TME of NSCLC. J Immunother Cancer. 2024;12(9):e009376.","journal-title":"J Immunother Cancer"},{"issue":"3","key":"793_CR176","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1038\/s41591-024-03418-4","volume":"31","author":"JSW Borgers","year":"2025","unstructured":"Borgers JSW, Lenkala D, Kohler V, Jackson EK, Linssen MD, Hymson S, et al. Personalized, autologous neoantigen-specific T cell therapy in metastatic melanoma: a phase 1 trial. Nat Med. 2025;31(3):881\u201393.","journal-title":"Nat Med"}],"container-title":["Experimental Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40164-026-00793-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40164-026-00793-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40164-026-00793-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T01:04:06Z","timestamp":1788224646000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40164-026-00793-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,19]]},"references-count":176,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["793"],"URL":"https:\/\/doi.org\/10.1186\/s40164-026-00793-1","relation":{},"ISSN":["2162-3619"],"issn-type":[{"value":"2162-3619","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,19]]},"assertion":[{"value":"26 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"84"}}